EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma

Andrea Timpanaro, Caroline Piccand, Anne-Christine Uldry iD, Peter Karl Bode, Dzhangar Dzhumashev, Rita Sala, Manfred Heller iD, Jochen Rössler iD, Michele Bernasconi iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24032601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Andrea Timpanaro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. Hauptthemen laut MEDLINE: Neural Cell Adhesion Molecule L1, Rhabdomyosarcoma. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bernese Foundation for Children and Young Adults with Cancer / Berner Stiftung für krebskranke Kinder und Jugendliche, Stiftung zur Krebsbekämpfung, Bernese Foundation for Children and Young Adults with Cancer/Berner Stiftung für krebskranke Kinder und Jugendliche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. The prognosis for patients with high-grade and metastatic disease is still very poor, and survivors are burdened with long-lasting side effects. Therefore, more effective and less toxic therapies are needed. Surface proteins are ideal targets for antibody-based therapies, like bispecific antibodies, antibody-drug conjugates, or chimeric antigen receptor (CAR) T-cells. Specific surface targets for RMS are scarce. Here, we performed a surfaceome profiling based on differential centrifugation enrichment of surface/membrane proteins and detection by LC-MS on six fusion-positive (FP) RMS cell lines, five fusion-negative (FN) RMS cell lines, and three RMS patient-derived xenografts (PDXs). A total of 699 proteins were detected in the three RMS groups. Ranking based on expression levels and comparison to expression in normal MRC-5 fibroblasts and myoblasts, followed by statistical analysis, highlighted known RMS targets such as FGFR4, NCAM1, and CD276/B7-H3, and revealed AGRL2, JAM3, MEGF10, GPC4, CADM2, as potential targets for immunotherapies of RMS. L1CAM expression was investigated in RMS tissues, and strong L1CAM expression was observed in more than 80% of alveolar RMS tumors, making it a practicable target for antibody-based therapies of alveolar RMS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neural Cell Adhesion Molecule L1RhabdomyosarcomaChildAnimalsHumansHeterograftsCell LineTranscription FactorsDisease Models, AnimalNeural Cell Adhesion MoleculesCell Line, TumorB7 AntigensCell Adhesion MoleculesReceptor, Fibroblast Growth Factor, Type 4CD56 Antigen

Stichwörter der Autor:innen

AGRL2JAM3L1CAMantibody-based therapiescell surface proteomicsrhabdomyosarcomatargeted therapies

Substanzen

Neural Cell Adhesion Molecule L1Transcription FactorsNeural Cell Adhesion MoleculesB7 AntigensCell Adhesion MoleculesReceptor, Fibroblast Growth Factor, Type 4CD276 protein, humanJAM3 protein, humanFGFR4 protein, humanNCAM1 protein, human

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Translational Cancer Research, Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.
  • Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland.
  • Proteomics & Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.
  • Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Children's Research Center, University Children's Hospital Zurich, University of Zurich, 3032 Zurich, Switzerland.

ORCID-Profile: Anne-Christine Uldry, Manfred Heller, Jochen Rössler, Michele Bernasconi

Förderung

  • Bernese Foundation for Children and Young Adults with Cancer / Berner Stiftung für krebskranke Kinder und Jugendliche
  • Stiftung zur Krebsbekämpfung
  • Bernese Foundation for Children and Young Adults with Cancer/Berner Stiftung für krebskranke Kinder und Jugendliche

Zitieren

APA

Timpanaro, A., Piccand, C., Uldry, A. C., Bode, P. K., Dzhumashev, D., Sala, R., Heller, M., Rössler, J., & Bernasconi, M. (2023). Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032601

Vancouver

Timpanaro A, Piccand C, Uldry AC, Bode PK, Dzhumashev D, Sala R, et al. Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032601

BibTeX
@article{Timpanaro2023,
  author = {Timpanaro, Andrea and Piccand, Caroline and Uldry, Anne-Christine and Bode, Peter Karl and Dzhumashev, Dzhangar and Sala, Rita and Heller, Manfred and Rössler, Jochen and Bernasconi, Michele},
  title = {Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24032601}
}
Kostenlos starten →